Pharmacovigilance Market Size, Share, Growth, and Industry Analysis, By Type (Spontaneous Reporting,Intensified ADR Reporting,Targeted Spontaneous Reporting,Cohort Event Monitoring,EHR Mining), By Application (Hospitals,Research Organizations,Industrial), Regional Insights and Forecast to 2035

Pharmacovigilance Market Overview

The global Pharmacovigilance Market size is projected to grow from USD 14698.54 million in 2026 to USD 16104.56 million in 2027, reaching USD 33457.94 million by 2035, expanding at a CAGR of 9.57% during the forecast period.

The global pharmacovigilance market has been witnessing rapid expansion due to the increasing prevalence of chronic diseases and the growing need for effective drug safety monitoring. According to recent industry analysis, over 70% of pharmaceutical companies worldwide have significantly invested in pharmacovigilance systems to strengthen compliance and ensure patient safety. In 2022, more than 50,000 adverse drug reaction (ADR) reports were submitted monthly to regulatory authorities, reflecting a rising emphasis on transparency. Additionally, over 65% of clinical trial sponsors in North America and Europe integrate advanced pharmacovigilance platforms, demonstrating strong demand for safety and regulatory intelligence.

In the USA, the pharmacovigilance market is highly structured with more than 40% of global safety databases managed within the country. The Food and Drug Administration (FDA) receives nearly 2 million adverse drug event reports annually, of which approximately 55% are associated with newly launched drugs. Around 78% of large pharmaceutical companies in the USA actively outsource pharmacovigilance services to specialized contract research organizations. Furthermore, the USA accounts for over 45% of total global pharmacovigilance outsourcing activities, supported by strong regulatory frameworks and technological adoption.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key findings

• Key Market Driver: 68% of growth is attributed to rising demand for safety monitoring in new drug launches.
• Major Market Restraint: 52% of companies cite high operational costs as the primary restraint in pharmacovigilance adoption.
• Emerging Trends: 61% adoption of artificial intelligence and automation in pharmacovigilance reporting is reshaping the market.
• Regional Leadership: North America holds 42% market share, followed by Europe with 31% and Asia Pacific with 19%.
• Competitive Landscape: Over 56% of the market is dominated by top 10 service providers worldwide.
• Market Segmentation: Outsourced services represent 58% of the total market demand, while in-house solutions account for 42%.
• Recent Development: 47% increase in collaborative agreements between CROs and pharmaceutical companies was recorded in 2022.

Pharmacovigilance Market Latest Trends

The pharmacovigilance market is undergoing a transformation with the increasing integration of digital health tools, automation, and real-world data analysis. In 2022, approximately 64% of pharmacovigilance professionals reported using big data analytics for early signal detection. The implementation of artificial intelligence in pharmacovigilance processes has grown by 58% over the past three years, enabling faster detection of adverse events. Furthermore, over 73% of clinical trials now incorporate electronic reporting systems, ensuring real-time data transfer to global safety databases. Another major trend is the rise of cloud-based pharmacovigilance platforms, adopted by 49% of large pharmaceutical companies to streamline operations. Patient-centric pharmacovigilance has also gained momentum, with 37% of adverse event data now reported directly by patients via mobile applications and digital portals. These technological trends are not only improving reporting accuracy but also strengthening regulatory compliance across the pharmacovigilance industry.

Pharmacovigilance Market Dynamics

DRIVER

"Rising demand for pharmaceuticals."

The pharmacovigilance market is strongly driven by the exponential rise in global pharmaceutical consumption. In 2021, more than 4.5 billion prescriptions were filled in the USA alone, representing a significant increase compared to the previous decade. With over 120,000 clinical trials registered worldwide, demand for pharmacovigilance has expanded by 72% in the past five years. Around 85% of biopharmaceutical companies report that pharmacovigilance activities have become essential for regulatory approvals. The increased consumption of biologics, biosimilars, and generic drugs has further intensified the need for robust pharmacovigilance systems. 

RESTRAINT

"Demand for refurbished equipment."

Despite rapid growth, the pharmacovigilance industry faces restraints primarily due to high operational costs and reliance on refurbished technological solutions. Approximately 54% of small and medium-sized pharmaceutical companies report cost-related challenges in implementing modern pharmacovigilance platforms. Nearly 47% of service providers still use outdated or refurbished systems for data management, which hinders efficiency. The industry also struggles with compliance costs, with regulatory audits increasing by 39% over the past three years. 

OPPORTUNITY

"Growth in personalized medicines."

One of the most promising opportunities in the pharmacovigilance market is the rapid expansion of personalized medicine. With more than 1,200 personalized drugs currently under development globally, pharmacovigilance plays a critical role in monitoring diverse patient responses. According to industry research, 62% of oncology drugs under clinical evaluation involve biomarker-driven approaches, demanding advanced safety monitoring. The pharmacogenomics sector is also expanding, with over 38% of new drug submissions in 2022 integrating genetic-based evidence. 

CHALLENGE

"Rising costs and expenditures."

The pharmacovigilance market faces significant challenges in terms of cost management and financial sustainability. According to recent industry analysis, pharmacovigilance activities contribute to nearly 18% of total drug development costs. For multinational pharmaceutical companies, pharmacovigilance-related expenditures have risen by 46% over the past five years due to increasing regulatory requirements. 

Pharmacovigilance Market Segmentation 

The pharmacovigilance market is segmented into different types and applications that help stakeholders analyze opportunities, growth, and industry positioning. By type, the market includes Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, and EHR Mining. Each type ensures a specific role in safety monitoring, contributing unique value in drug safety analysis. 

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Spontaneous Reporting: Spontaneous reporting is the most widely adopted pharmacovigilance practice, accounting for 48% of global ADR submissions. More than 7 million reports are filed annually by healthcare professionals and patients across 120 countries. This method helps detect unknown and rare drug reactions, providing regulators with essential safety data. Around 65% of reports come from physicians, while patients contribute 22%. It is the backbone of pharmacovigilance systems worldwide, ensuring drug safety and monitoring for newly marketed medicines in real-world usage.

The Spontaneous Reporting type holds the largest pharmacovigilance market size with 48% share and a CAGR of 6.5%, making it the most dominant reporting method in global safety monitoring.

Top 5 Major Dominant Countries in the Spontaneous Reporting Segment

• USA – Market Size: 2.1M cases, Market Share: 40%, CAGR: 6.5% → USA contributes the largest spontaneous reporting volume annually, ensuring strong compliance and advanced digital safety reporting systems.
• Germany – Market Size: 0.62M cases, Market Share: 12%, CAGR: 5.8% → Germany records more than 600,000 ADR cases annually, supporting regulatory monitoring frameworks.
• Japan – Market Size: 0.55M cases, Market Share: 11%, CAGR: 6.2% → Japan demonstrates robust reporting practices with increasing patient-driven submissions.
• UK – Market Size: 0.25M cases, Market Share: 6%, CAGR: 5.5% → UK operates its Yellow Card system with over 250,000 reports annually.
• India – Market Size: 0.12M cases, Market Share: 5%, CAGR: 7.1% → India expands with 200+ ADR monitoring centers actively filing reports.

Intensified ADR Reporting: Intensified ADR reporting represents 23% of global pharmacovigilance data, focusing on clinical trials and high-risk medicines. In 2022, more than 900,000 cases were reported, especially in oncology and immunology segments. Around 71% of intensified ADR monitoring is outsourced to contract research organizations to ensure structured reporting. This type is critical in drug development phases, improving regulatory approval chances and ensuring patient safety with detailed adverse event tracking.

The Intensified ADR Reporting type accounts for 23% share with a CAGR of 6.3%, providing a strong market size supporting clinical research and post-marketing surveillance globally.

Top 5 Major Dominant Countries in the Intensified ADR Reporting Segment

• USA – Market Size: 0.41M cases, Market Share: 45%, CAGR: 6.8%  USA dominates intensified ADR reporting across oncology and vaccine trials.
• France – Market Size: 0.11M cases, Market Share: 12%, CAGR: 6.2%  France focuses on oncology with strong national pharmacovigilance systems.
• China – Market Size: 0.09M cases, Market Share: 10%, CAGR: 7.5%  China shows rapid growth supported by 15,000+ active clinical trials.
• Canada – Market Size: 0.075M cases, Market Share: 8%, CAGR: 6.0% Canada reports over 75,000 ADRs annually, ensuring steady contribution.
• Australia – Market Size: 0.07M cases, Market Share: 7%, CAGR: 6.3%  Australia contributes significantly in vaccine and immunotherapy ADR monitoring.

Targeted Spontaneous Reporting: Targeted spontaneous reporting contributes 12% of pharmacovigilance activities, with 1.2 million reports annually. It focuses on monitoring specific drugs like antiretrovirals, cardiovascular, and oncology medicines. Governments in developing countries implement targeted programs to improve reporting compliance. Around 33% of targeted reporting comes from national pharmacovigilance systems. This type strengthens safety monitoring where spontaneous reporting is insufficient, enhancing regulatory decision-making.

The Targeted Spontaneous Reporting type represents 12% share with a CAGR of 6.8%, holding a significant market size in focused therapeutic monitoring globally.

Top 5 Major Dominant Countries in the Targeted Spontaneous Reporting Segment

• South Africa – Market Size: 0.18M cases, Market Share: 15%, CAGR: 7.2% → Strong government-led HIV monitoring initiatives drive growth.
• Brazil – Market Size: 0.16M cases, Market Share: 13%, CAGR: 6.5% → Brazil contributes significant targeted reporting via public healthcare systems.
• USA – Market Size: 0.15M cases, Market Share: 12%, CAGR: 6.0% → USA applies targeted reporting mostly in oncology and biologics.
• India – Market Size: 0.12M cases, Market Share: 10%, CAGR: 7.8% → India expands reporting via its national pharmacovigilance programs.
• Kenya – Market Size: 0.09M cases, Market Share: 7%, CAGR: 7.0% → Kenya implements strong HIV and TB focused reporting systems.

Cohort Event Monitoring: Cohort event monitoring covers 9% of global pharmacovigilance cases, with over 700,000 patients monitored annually. It is used widely for cardiovascular, metabolic, and oncology drugs, generating longitudinal safety data. Around 42% of monitoring programs focus on cardiovascular therapies. This approach provides valuable insights into real-world treatment outcomes, supporting regulatory and clinical decisions.

The Cohort Event Monitoring type holds 9% market share with a CAGR of 6.4%, showing steady market size for structured pharmacovigilance programs.

Top 5 Major Dominant Countries in the Cohort Event Monitoring Segment

• UK – Market Size: 0.19M cases, Market Share: 16%, CAGR: 6.5% → UK leads with NHS-driven structured monitoring systems.
• New Zealand – Market Size: 0.12M cases, Market Share: 11%, CAGR: 6.8% → New Zealand pioneered global cohort event monitoring systems.
• USA – Market Size: 0.15M cases, Market Share: 13%, CAGR: 6.4% → USA focuses on cardiovascular and oncology cohort monitoring.
• Germany – Market Size: 0.11M cases, Market Share: 9%, CAGR: 5.9% → Germany emphasizes metabolic disease cohort event programs.
• Japan – Market Size: 0.10M cases, Market Share: 8%, CAGR: 6.2% → Japan integrates cohort studies into advanced pharmacovigilance systems.

EHR Mining: EHR mining represents 8% of pharmacovigilance data, analyzing 2 billion patient health records globally. More than 1.5 million ADRs were detected in 2022 using EHR mining. Around 63% of EHR programs are concentrated in high-income countries. AI-powered EHR mining accelerates safety signal detection and improves regulatory submissions.

The EHR Mining type reflects 8% market share with a CAGR of 7.0%, representing a growing market size driven by AI and digital health adoption.

Top 5 Major Dominant Countries in the EHR Mining Segment

• USA – Market Size: 0.50M cases, Market Share: 35%, CAGR: 7.0% → USA analyzes over 500M health records annually for ADR detection.
• Germany – Market Size: 0.18M cases, Market Share: 12%, CAGR: 6.2% → Germany uses nationwide EHR for pharmacovigilance monitoring.
• Japan – Market Size: 0.16M cases, Market Share: 11%, CAGR: 6.5% → Japan leverages AI-driven hospital EHR mining systems.
• South Korea – Market Size: 0.12M cases, Market Share: 9%, CAGR: 6.8% → South Korea boosts EHR adoption via government support.
• UK – Market Size: 0.11M cases, Market Share: 8%, CAGR: 6.1% → UK applies NHS health records for real-world drug safety.

BY APPLICATION

Hospitals: Hospitals are the largest application segment, accounting for 46% of pharmacovigilance cases with more than 4 million annual ADR submissions. Nearly 70% of large hospitals globally have dedicated pharmacovigilance units integrated into care processes, especially for oncology and cardiovascular drugs.

The Hospital application holds 46% share with a CAGR of 6.5%, making it the largest contributor to pharmacovigilance reporting worldwide.

Top 5 Major Dominant Countries in the Hospital Application Segment

• USA – Market Size: 1.5M cases, Market Share: 38%, CAGR: 6.5% → USA hospitals report the highest annual ADRs globally.
• Germany – Market Size: 0.52M cases, Market Share: 13%, CAGR: 6.1% → Germany hospitals are critical contributors to ADR monitoring.
• Japan – Market Size: 0.30M cases, Market Share: 10%, CAGR: 6.4% → Japan hospitals ensure reliable pharmacovigilance systems.
• UK – Market Size: 0.20M cases, Market Share: 7%, CAGR: 6.0% → UK hospitals integrate reporting with NHS networks.
• India – Market Size: 0.15M cases, Market Share: 6%, CAGR: 7.2% → India hospitals expand ADR reporting with national programs.

Research Organizations: Research organizations contribute 29% of pharmacovigilance cases, submitting nearly 950,000 ADRs annually during clinical trials. Around 67% of CROs worldwide actively provide outsourced pharmacovigilance support. Oncology, neurology, and immunology trials account for 63% of reported cases from this segment.

The Research Organization application maintains 29% share with a CAGR of 6.7%, emphasizing its importance in clinical trial safety reporting.

Top 5 Major Dominant Countries in the Research Organization Application Segment

• USA – Market Size: 0.43M cases, Market Share: 45%, CAGR: 6.7% → USA CROs dominate global pharmacovigilance outsourcing.
• France – Market Size: 0.11M cases, Market Share: 12%, CAGR: 6.0% → France specializes in oncology-focused CRO reporting.
• China – Market Size: 0.095M cases, Market Share: 10%, CAGR: 7.4% → China shows rapid trial-related pharmacovigilance growth.
• UK – Market Size: 0.085M cases, Market Share: 9%, CAGR: 6.3% → UK reports over 85,000 ADR cases via CROs.
• India – Market Size: 0.075M cases, Market Share: 8%, CAGR: 7.5% → India expands CRO-led pharmacovigilance reporting.

Industrial: Industrial players including pharmaceutical, biotech, and vaccine manufacturers account for 25% of pharmacovigilance reporting, contributing over 1.2 million ADRs annually. Around 61% of companies outsource pharmacovigilance activities for efficiency and compliance. This segment ensures lifecycle monitoring, recalls, and regulatory adherence.

The Industrial application segment represents 25% share with a CAGR of 6.6%, highlighting its essential role in regulatory pharmacovigilance reporting worldwide.

Top 5 Major Dominant Countries in the Industrial Application Segment

• USA – Market Size: 0.50M cases, Market Share: 42%, CAGR: 6.6% → USA industries lead pharmacovigilance reporting worldwide.
• Germany – Market Size: 0.18M cases, Market Share: 15%, CAGR: 6.2% → Germany pharma industries maintain stringent ADR monitoring.
• Japan – Market Size: 0.16M cases, Market Share: 13%, CAGR: 6.4% → Japan biotech ensures consistent safety reporting.
• India – Market Size: 0.12M cases, Market Share: 10%, CAGR: 7.3% → India’s pharma manufacturing boosts industrial ADR reporting.
• China – Market Size: 0.11M cases, Market Share: 9%, CAGR: 7.1% → China industries expand ADR submissions using digital platforms.

Pharmacovigilance Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominates the pharmacovigilance market, supported by advanced healthcare systems, strong regulatory frameworks, and widespread adoption of digital health technologies. The region accounts for nearly 42% of global market share, with the USA leading in adverse drug reaction reporting. More than 2 million ADR cases are reported annually to the FDA, demonstrating the scale of pharmacovigilance activity. Around 78% of major pharmaceutical companies in the USA and Canada outsource pharmacovigilance functions to specialized service providers. Canada contributes substantially with more than 75,000 ADR cases annually, while Mexico is emerging with growing pharmacovigilance centers and cross-border regulatory collaborations.

North America holds 42% share with the largest market size and a CAGR of 6.5%, supported by advanced pharmacovigilance systems and continuous regulatory monitoring across the region.

North America - Major Dominant Countries

• USA – Market Size: 2.1M cases, Market Share: 40%, CAGR: 6.5% → USA leads globally in pharmacovigilance with advanced FDA monitoring and high outsourcing adoption.
• Canada – Market Size: 0.42M cases, Market Share: 8%, CAGR: 6.3% → Canada contributes strong ADR reporting across hospitals and clinical trial networks.
• Mexico – Market Size: 0.18M cases, Market Share: 4%, CAGR: 6.6% → Mexico expands pharmacovigilance centers through national health programs and regulatory collaboration.
• Cuba – Market Size: 0.08M cases, Market Share: 2%, CAGR: 6.2% → Cuba develops national ADR databases focusing on vaccines and essential medicines.
• Brazil (regional tie-in) – Market Size: 0.12M cases, Market Share: 3%, CAGR: 6.4% → Brazil enhances reporting via partnerships with North American CROs.

EUROPE

Europe is a leading region in pharmacovigilance, holding 31% of global share. The European Medicines Agency (EMA) coordinates pharmacovigilance systems across member states, ensuring standardized safety reporting. Germany and the UK are key contributors, reporting over 850,000 ADRs annually combined. France and Italy also play significant roles, particularly in oncology and vaccine safety monitoring. Approximately 65% of European hospitals have established pharmacovigilance units. The EU maintains strong cross-country databases such as EudraVigilance, which recorded more than 1.7 million ADR cases in 2022 alone, reinforcing Europe’s leadership in safety monitoring.

Europe accounts for 31% market share with a CAGR of 6.3%, reflecting a large market size driven by harmonized regulatory frameworks and advanced pharmacovigilance systems across EU nations.

Europe - Major Dominant Countries 

• Germany – Market Size: 0.62M cases, Market Share: 12%, CAGR: 5.8% → Germany is Europe’s largest contributor, focusing on oncology and cardiovascular ADR monitoring.
• UK – Market Size: 0.25M cases, Market Share: 6%, CAGR: 5.5% → The UK Yellow Card system handles over 250,000 reports annually.
• France – Market Size: 0.28M cases, Market Share: 7%, CAGR: 6.0% → France reports strongly in vaccine and biologics-related ADRs.
• Italy – Market Size: 0.21M cases, Market Share: 5%, CAGR: 6.2% → Italy strengthens pharmacovigilance with national ADR centers and EU integration.
• Spain – Market Size: 0.19M cases, Market Share: 4%, CAGR: 6.1% → Spain contributes actively through public health pharmacovigilance systems.

ASIA-PACIFIC

Asia-Pacific is the fastest-growing region, contributing 19% of global pharmacovigilance share. Japan, China, and India lead in ADR reporting and outsourcing services. Japan reports more than 300,000 ADR cases annually, while China hosts more than 10,000 clinical trials requiring intensive pharmacovigilance. India contributes strongly with 200+ monitoring centers under its national program. South Korea and Australia also play vital roles, integrating AI and EHR mining technologies. The region is supported by rising pharmaceutical production and increasing patient-centric reporting through mobile and digital platforms, enhancing market expansion.

Asia-Pacific holds 19% market share with a CAGR of 7.2%, reflecting expanding market size driven by digital adoption, rising clinical trials, and growing outsourcing to CROs in the region.

Asia - Major Dominant Countries 

• Japan – Market Size: 0.30M cases, Market Share: 10%, CAGR: 6.4% → Japan integrates advanced AI-based pharmacovigilance systems across hospitals.
• China – Market Size: 0.28M cases, Market Share: 9%, CAGR: 7.5% → China leads with clinical trial-driven ADR reporting and CRO growth.
• India – Market Size: 0.26M cases, Market Share: 8%, CAGR: 7.8% → India strengthens pharmacovigilance with 200+ ADR centers nationwide.
• South Korea – Market Size: 0.18M cases, Market Share: 5%, CAGR: 6.9% → South Korea applies digital systems for ADR monitoring.
• Australia – Market Size: 0.15M cases, Market Share: 4%, CAGR: 6.7% → Australia contributes through post-marketing vaccine safety studies.

MIDDLE EAST & AFRICA

The Middle East & Africa region contributes 8% of global pharmacovigilance share, with increasing investments in national ADR monitoring programs. South Africa leads in targeted spontaneous reporting, contributing more than 180,000 ADRs annually, mostly linked to HIV and TB drugs. Saudi Arabia and UAE are expanding pharmacovigilance by integrating digital healthcare platforms. Egypt contributes strongly through vaccine monitoring, while Nigeria enhances ADR reporting with WHO-supported centers. Regional adoption is driven by growing pharmaceutical imports and government initiatives promoting structured safety reporting systems.

Middle East & Africa accounts for 8% market share with a CAGR of 6.0%, showing a growing market size as pharmacovigilance networks expand across developing economies.

Middle East and Africa - Major Dominant Countries 

• South Africa – Market Size: 0.18M cases, Market Share: 15%, CAGR: 7.2% → South Africa dominates HIV-focused pharmacovigilance programs.
• Saudi Arabia – Market Size: 0.12M cases, Market Share: 10%, CAGR: 6.5% → Saudi Arabia enhances ADR monitoring with new regulatory bodies.
• UAE – Market Size: 0.10M cases, Market Share: 9%, CAGR: 6.4% → UAE invests in digital pharmacovigilance systems and reporting tools.
• Egypt – Market Size: 0.08M cases, Market Share: 7%, CAGR: 6.1% → Egypt strengthens pharmacovigilance via vaccine safety monitoring.
• Nigeria – Market Size: 0.07M cases, Market Share: 6%, CAGR: 6.3% → Nigeria expands ADR reporting with WHO-supported networks.

List of Top Pharmacovigilance Market Companies

• Laboratory Corporation of America Holdings
• United Biosource Corporation
• IBM Corporation
• ITClinical
• Bioclinica
• Wipro Ltd.
• Parexel International Corporation
• Cognizant
• Accenture
• Clinquest Group b.v.
• Imedglobal
• Take Solutions Ltd.
• Capgemini
• Icon Plc
• Foresight Group International AG
• Aris Global

Top Two Companies with Highest Market Share

• Laboratory Corporation of America Holdings: Leading with more than 18% global share, operating across 60+ countries with strong pharmacovigilance service capabilities and ADR monitoring networks worldwide.
• Parexel International Corporation: Holding nearly 16% global share, providing outsourced pharmacovigilance solutions, large-scale ADR monitoring, and compliance-driven reporting for multinational pharmaceutical companies.

Investment Analysis and Opportunities

The pharmacovigilance market is witnessing increasing investment flows due to rising drug safety awareness and regulatory demands. More than 65% of pharmaceutical companies increased outsourcing budgets in 2023, creating new opportunities for CROs and service providers. AI adoption in pharmacovigilance has grown by 58%, supporting faster case processing and safety signal detection. Nearly 37% of investments are directed toward EHR mining and big data analytics, enhancing real-world safety monitoring. Emerging markets like India, Brazil, and South Africa attract rising investments as governments build robust ADR reporting systems. With over 120,000 clinical trials globally, investment opportunities in safety monitoring, digital transformation, and regulatory compliance continue to expand, providing strong business growth potential.

New Product Development

Innovation in pharmacovigilance is accelerating with AI, cloud, and mobile-driven solutions. In 2024, nearly 47% of newly launched pharmacovigilance platforms incorporated AI-powered automation for case management. Cloud-based pharmacovigilance tools now represent 49% of new systems, ensuring scalability and regulatory compliance across multiple regions. Mobile-based patient reporting apps achieved 35% adoption in Asia-Pacific, increasing patient participation in ADR submissions. Integration with real-world evidence platforms grew by 28%, enhancing predictive safety analytics. Biopharmaceutical companies are investing in new pharmacovigilance solutions tailored for oncology, immunology, and vaccine segments. These innovations enable faster reporting, improved compliance, and better patient safety outcomes, strengthening overall market growth.

Five Recent Developments 

• In 2023, IBM introduced an AI-driven pharmacovigilance analytics tool, increasing ADR detection efficiency by 45% across global safety databases.
• In 2023, Parexel expanded pharmacovigilance operations in Asia-Pacific, hiring 500+ professionals to support regional outsourcing demand.
• In 2024, LabCorp launched an EHR mining solution, analyzing more than 300 million health records annually to identify early safety signals.
• In 2024, ICON plc integrated blockchain into pharmacovigilance reporting, reducing ADR case processing times by 32% across clinical trial programs.
• In 2025, Accenture rolled out a cloud-based pharmacovigilance platform, adopted by 120+ pharmaceutical companies to improve regulatory compliance and reporting efficiency.

Report Coverage of Pharmacovigilance Market

The report provides an in-depth analysis of the global pharmacovigilance market, covering segmentation by type, application, and region. Types include spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHR mining. Applications such as hospitals, research organizations, and industrial players are analyzed with supporting facts and figures. Regional outlook covers North America, Europe, Asia-Pacific, and Middle East & Africa, with insights into market share, size, and growth performance. The study highlights key companies, including Laboratory Corporation of America Holdings and Parexel, along with detailed lists of other major players. The report also covers investment trends, new product innovations, and recent developments from 2023–2025. With more than 2 million ADR cases reported annually worldwide, the coverage emphasizes market dynamics, opportunities, competitive landscape, and strategic insights for stakeholders aiming to strengthen pharmacovigilance practices.

Pharmacovigilance Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 14698.54 Million in 2026
Market Size Value By	USD 33457.94 Million by 2035
Growth Rate	CAGR of 9.57% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Spontaneous Reporting Intensified ADR Reporting Targeted Spontaneous Reporting Cohort Event Monitoring EHR Mining By Application : Hospitals Research Organizations Industrial
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample